NEW YORK--(BUSINESS WIRE)--Feb. 7, 2018--
Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, today announced that
Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will
participate in a fireside chat at the Leerink Partners 7th
Annual Global Healthcare Conference in New York City. The fireside chat
will take place on Wednesday, February 14, 2018, at 2:00 p.m. Eastern
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging,
clinical-stage biotechnology company focused on developing
first-in-class gene therapy treatment options for rare, undertreated
diseases. Rocket’s multi-platform development approach applies the
well-established lentiviral vector (LVV) and adeno-associated viral
vector (AAV) gene therapy platforms. Rocket's lead clinical program is a
LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a
difficult to treat genetic disease that leads to bone marrow failure and
potentially cancer. Preclinical studies of additional bone
marrow-derived disorders are ongoing and target Pyruvate Kinase
Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile
Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based
gene therapy program for an undisclosed rare pediatric disease. For more
information about Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180207005145/en/
Source: Rocket Pharmaceuticals, Inc.
Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
The Alexandria Center for Life Science
29 Street, Suite 1040
New York, NY 10016